LTRN Lantern: Rasio nilai perusahaan marang pendapatan

Lantern (LTRN) - logo korporat

Lantern Pharma Inc. (LTRN) is implementing the RADR AI system for high-precision modeling of lung cancer therapy. The EV-to-revenue multiple visualizes the market value of the debt-free business, where the latest parameter stands at 0.00. Synergy with research institutes and cloud services optimizes patient selection. Growing demand for predictive platforms is expanding the customer base among pharmaceutical developers.

LTRN (Lantern) riwayat Multiplikator EV/Sales saka 23.11.2025 nganti 20.11.2026

LTRN (Lantern Pharma Inc): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental:Lantern LTRN
Sampel barang Lantern Pharma

To objectively evaluate Lantern Pharma Inc. (LTRN), it is necessary to analyze the enterprise value relative to sales, excluding debt load. The EV/Sales trend reflects the market price of assets per unit of revenue, allowing for a determination of the overvaluation of the AI platform for targeted drug discovery. This helps investors decouple speculative interest in cancer therapy innovations from the actual capitalization of the company's fundamental potential.